Aortic & peripheral vascular diseaseSecondary analysis

Paclitaxel-Coated Devices in Patients With Chronic Limb-Threatening Ischemia and Tissue Loss Undergoing Infrainguinal Endovascular Revascularization: Insights From the SWEDEPAD-1 Trial

Circ Cardiovasc IntervPublished

  • post hoc subgroup analysis
  • multicenter registry-based randomized controlled trial
  • randomized 1:1
  • intention-to-treat analyses
  • adjusted Cox proportional hazards models

Authors' conclusion

In patients with chronic limb-threatening ischemia and tissue loss, paclitaxel-coated devices did not improve limb salvage and were associated with a higher early risk of major amputation. Although target vessel reintervention was reduced at 1 year, this apparent benefit was not maintained when accounting for the competing risk of limb loss in a composite end point.

Study context

Population
Adults with chronic limb-threatening ischemia and tissue loss (Rutherford 5 or 6) undergoing infrainguinal endovascular treatment in SWEDEPAD-1patients with tissue loss (median age, 77 years, 60.1% male, 58.4% diabetes)
Participants
1,761 adults
Comparison
paclitaxel-coated or uncoated endovascular devices
Primary endpoint
Time to ipsilateral major amputation
Follow-up
3 months, 1 year, and 5 years

Primary result

As reported in the abstract

Adjusted hazard ratio

1.43

95% CI 1.04–1.96

By group

paclitaxel-coated group

10.4%

within 3 months · 1 year 16.3%

uncoated group

7.5%

within 3 months · 1 year 14.6%

paclitaxel-coated group vs uncoated group
adjusted hazard ratio 1.43 (95% CI 1.04–1.96)

Secondary outcomes

Outcomepaclitaxel-coated groupuncoated groupadjusted hazard ratio (95% CI)
Target vessel reintervention · 1 year · lower with paclitaxel-coated devices · secondary end point13.6%18.0%0.77 (0.61–0.97)

Composite of major amputation or target vessel reintervention

Difference attenuated when early limb loss was included in a composite end point
No significant between-group differences at 5 years
  • secondary end point

Original publication

Paclitaxel-Coated Devices in Patients With Chronic Limb-Threatening Ischemia and Tissue Loss Undergoing Infrainguinal Endovascular Revascularization: Insights From the SWEDEPAD-1 Trial. Circ Cardiovasc Interv. Published 24 September 2026. doi:10.1161/circinterventions.126.016977

Summarised from the published abstract; every number is checked against it